Market Overview

UPDATE: Goldman Sachs Upgrades Stryker Corporation to Buy on Organic Growth, Capital Allocation

Related SYK
Stryker Completes Berchtold Acquisition - Analyst Blog
Bio-Rad Buys GnuBio - Analyst Blog

Goldman Sachs raised its rating on Stryker Corporation (NYSE: SYK) from Neutral to Buy and increased its price target from $55 to $68.

Goldman Sachs noted, "Our thesis calls for improvements in both operational and financial performance as follows: (1) new CEO and a reset of expectations for 2013; (2) strong product portfolio/pipeline and diversified revenue base offer multiple growth opportunities; (3) shareholder-friendly capital allocation with a greater orientation to cash returns; (4) cost and quality control initiatives remain a source of margin opportunity; and (5) attractive relative valuation compared to other large-cap MedTech firms in our coverage universe."

Stryker Corporation closed at $54.57 on Monday.

Posted-In: Goldman SachsAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (SYK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free